These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32130336)

  • 1. Cost of precision medicine at a referral center for cystic fibrosis.
    Marson FAL
    J Bras Pneumol; 2020 Mar; 46(2):e20190308. PubMed ID: 32130336
    [No Abstract]   [Full Text] [Related]  

  • 2. Making precision medicine personal for cystic fibrosis.
    Manfredi C; Tindall JM; Hong JS; Sorscher EJ
    Science; 2019 Jul; 365(6450):220-221. PubMed ID: 31320522
    [No Abstract]   [Full Text] [Related]  

  • 3. New cystic fibrosis drug paves the way for orphan diseases.
    Cooney D
    Lancet Respir Med; 2013 Apr; 1(2):104. PubMed ID: 24429084
    [No Abstract]   [Full Text] [Related]  

  • 4. [Challenges of personalized medicine for cystic fibrosis].
    Corvol H; Taytard J; Tabary O; Le Rouzic P; Guillot L; Clement A
    Arch Pediatr; 2015 Jul; 22(7):778-86. PubMed ID: 26021452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new era of personalized medicine for cystic fibrosis - at last!
    Quon BS; Wilcox PG
    Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary nasal epithelial cells from patients with cystic fibrosis hold promise for guiding precision medicine and expanding treatment.
    Reeves SR
    Eur Respir J; 2021 Dec; 58(6):. PubMed ID: 34857588
    [No Abstract]   [Full Text] [Related]  

  • 7. Personalized medicine for cystic fibrosis: establishing human model systems.
    Mou H; Brazauskas K; Rajagopal J
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S14-23. PubMed ID: 26335952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision Genomic Medicine in Cystic Fibrosis.
    Chang EH; Zabner J
    Clin Transl Sci; 2015 Oct; 8(5):606-10. PubMed ID: 26073768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic fibrosis - an example of personalized and precision medicine.
    Skov M; Hansen CR; Pressler T
    APMIS; 2019 May; 127(5):352-360. PubMed ID: 30761610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.
    McCague AF; Raraigh KS; Pellicore MJ; Davis-Marcisak EF; Evans TA; Han ST; Lu Z; Joynt AT; Sharma N; Castellani C; Collaco JM; Corey M; Lewis MH; Penland CM; Rommens JM; Stephenson AL; Sosnay PR; Cutting GR
    Am J Respir Crit Care Med; 2019 May; 199(9):1116-1126. PubMed ID: 30888834
    [No Abstract]   [Full Text] [Related]  

  • 11. New and emerging targeted therapies for cystic fibrosis.
    Quon BS; Rowe SM
    BMJ; 2016 Mar; 352():i859. PubMed ID: 27030675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalised medicine in cystic fibrosis is unaffordable.
    Balfour-Lynn IM
    Paediatr Respir Rev; 2014 Jun; 15 Suppl 1():2-5. PubMed ID: 24832698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Medicine: At What Price?
    Ferkol T; Quinton P
    Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804
    [No Abstract]   [Full Text] [Related]  

  • 14. Cystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review.
    De la Hoz D; Villamil Osorio M; Restrepo-Gualteros SM
    Arch Argent Pediatr; 2019 Apr; 117(2):e131-e136. PubMed ID: 30869491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evidence-based treatment of cystic fibrosis].
    Ringshausen FC; Hellmuth T; Dittrich AM
    Internist (Berl); 2020 Dec; 61(12):1212-1229. PubMed ID: 33201261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
    Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
    Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
    [No Abstract]   [Full Text] [Related]  

  • 17. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.
    Becq F
    Drugs; 2010 Feb; 70(3):241-59. PubMed ID: 20166764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalised medicine in advanced cystic fibrosis.
    McKone EF
    Lancet Respir Med; 2016 Aug; 4(8):594-595. PubMed ID: 27298016
    [No Abstract]   [Full Text] [Related]  

  • 19. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel, mechanism-based therapies for cystic fibrosis.
    Rubenstein RC
    Curr Opin Pediatr; 2005 Jun; 17(3):385-92. PubMed ID: 15891431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.